Wait, What?
Menu
Sign inSaved storiesWhat is Wait, What?◎TopicsGive Feedback
For the best experience, download the app.Get Wait, What? on your phone.
App StorePlay Store
Wait, What?

Understand what happened, why it matters, and what comes next.

AboutFeedbackPrivacyPrivacy choices
For the best experience, download the app.Get Wait, What? on your phone.
App StorePlay Store
India

Cancer medicines see cuts up to 96.45% under new prices

Government price controls give patients greater protection from excessive medicine markups.

9 Nov 2026

Overview

Cancer patients and their families should start seeing lower prices for many medicines, but savings will vary by pharmacy and supply. New for 1,364 formulations across 121 drugs took effect nationwide on 9 November 2026, after 85 companies reported prices. The change followed an decision to limit to 30% for 137 anti-cancer drugs. Among the reported brands, 679 had price cuts above 50%. The biggest cut was 96.45%.

The government estimates yearly savings of ₹3,540.38 crore, but this is not guaranteed for every patient. Check the MRP on the newest pack and ask for an itemised bill. Keep the pack and receipt if a pharmacy charges the old price. The policy will depend on new stock reaching pharmacies, companies and distributors following the rules, and action against violations.

Sources
pib.gov.in ↗thehindubusinessline.com ↗businesstoday.in ↗pib.gov.in ↗theweek.in ↗economictimes.com ↗theweek.in ↗The Hindu ↗indiatvnews.com ↗zeebiz.com ↗news.abplive.com ↗The Hawk ↗Rediff MoneyWiz ↗CNBC TV18 ↗policyedge.in ↗newindianexpress.com ↗pib.gov.in ↗

Timeline

9 Nov 2026

Pharmacies and hospitals must implement the revised cancer-medicine prices

Manufacturers must communicate revised prices to retailers and hospitals, while pharmacies and hospitals must charge the reduced prices and display them from November 9, 2026. Consumers can use official channels to verify prices and report overcharging.

9 Nov 2026

Patients are told to verify revised MRPs and use official complaint channels

Patients should check the revised printed on the medicine pack and verify prices through the or website. Overcharging complaints can be submitted through the or helpline.

9 Nov 2026

The government projects annual consumer savings of ₹3,540.38 crore

The government estimated that the revised prices could save consumers each year. This is a projection based on the affected medicines and expected consumption, not a guaranteed identical saving for every patient. Actual savings depend on the medicine prescribed, the brand available and the price charged by the pharmacy.

9 Nov 2026

Revised MRPs for 1,364 anti-cancer formulations take effect

The came into effect nationwide on 9 November 2026. Pharmacies and companies were expected to use the updated MRP for covered products and reflect it on packaging, billing and sale records. The effective date marked the shift from reported price revisions to prices applicable at the point of sale.

8 Nov 2026

Companies report price reductions above 50 percent for 679 cancer-drug brands

The reported reductions varied by medicine and brand rather than applying uniformly across all products. Among the reported brands, showed price cuts of more than 50%. The highest reported reduction was 96.45%, which represents the maximum reported cut, not the typical reduction.

Sponsored
8 Nov 2026

Eighty-five pharmaceutical companies report revised prices for 1,364 formulations

By 8 November, 85 pharmaceutical companies had reported revised MRPs for 1,364 anti-cancer s covering 121 drugs. A drug refers to the active medicine, while a identifies a specific strength, dosage form or pack, and a brand is the company’s marketed product. The reported total therefore measures individual products and packs, not 1,364 separate medicines.

Oct 2026

NPPA caps trade margins on 137 anti-cancer drugs

The National Pharmaceutical Pricing Authority, operating under the Department of Pharmaceuticals, applied a to the MRP of 137 anti-cancer drugs. The measure used , with the margin capped at 30% of MRP. The policy was intended to reduce retail prices across participating brands.

17 Oct 2026

A DGHS expert committee recommends limiting trade margins on cancer medicines

The constituted an expert committee to address the affordability of anti-cancer medicines. Its recommendation focused on controlling trade margins and lowering maximum retail prices, rather than providing a general patient subsidy. The recommendation became the basis for the subsequent NPPA intervention.